Hemab Therapeutics Holdings, Inc. (COAG) stock
COAGNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 10, 2026
$39.29−0.57 (-1.43%)
Close on Nov 20, 2026Market cap $1.84BP/E –Yield –
Hemab Therapeutics free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
Quarterly free cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$28.33M | – |
| Q2 FY2026 | Jun 30, 2026 | -$22.66M | – |
| Q1 FY2026 | Mar 31, 2026 | -$21.70M | – |
| Q3 FY2025 | Sep 30, 2025 | -$16.40M | – |
| Q2 FY2025 | Jun 30, 2025 | -$15.33M | – |
| Q1 FY2025 | Mar 31, 2025 | -$13.05M | – |
See a number that looks wrong?